Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences
BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Tango Therapeutics management is scheduled to participate in three upcoming investment bank conferences. The B Riley Precision Oncology & Radiopharma Conference will be held in New York, NY in late February. The Leerink Global Healthcare Conference and Barclays 27th Annual Global Healthcare Conference will be held in Miami, FL in March.
B Riley Precision Oncology & Radiopharma Conference
- Panel participation on Friday, February 28 at 9:00-10:00 AM ET
- Panel title “Pushing Tumors Over the Edge with Synthetic Lethality”
Leerink Global Healthcare Conference
- Fireside chat on Wednesday, March 12 at 2:20-2:50 PM ET
- Webcast link
Barclays 27th Annual Global Healthcare Conference
- Available for 1x1 meetings on Thursday, March 13
The live webcast for each event will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit .
Investor Contact:
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
Media Contact:
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
Source: Tango Therapeutics, Inc.
